Joseph Blaney received his Ph.D. degree in microbiology and immunology from the Pennsylvania State University College of Medicine, Penn, USA, in 1999 while studying T-cell-based vaccines. After joining the Laboratory of Infectious Diseases (LID), NIAID, NIH, in 1999, he developed and characterized recombinant, live-attenuated dengue virus vaccine candidates. As a staff scientist in LID, he produced and evaluated vaccine seed stocks for several identified dengue vaccines and a west Nile virus vaccine candidate. Clinical lots of these vaccine candidates were found to be safe and immunogenic in humans, and the dengue candidates are now licensed throughout the world for development of a tetravalent vaccine. In 2008, Dr. Blaney joined the Emerging Viral Pathogens Section, NIAID, where he is currently investigating monkeypox and cowpox virus pathogenesis and developing bivalent vaccines that confer protection from rabies and Ebolavirus. Inactivated vaccines are being pursued for use in humans, and live vaccines are being developed for protection of endangered nonhuman primate populations in Africa. His main areas of interest include vaccine development, viral pathogenesis and immunology, and emerging infectious diseases.
Biography Updated on 21 May 2012